Resverlogix Corp.

Board of Directors

Donald J. McCaffrey, President and CEO, Co-Founder



Donald McCaffrey is President & Chief Executive Officer (CEO) of Resverlogix Corp. He has over 35 years of business experience including 15 years of drug discovery & development. Donald has led Resverlogix through significant changes and achievements from its initial days as a private company to becoming a TSX listed company. He has personally raised over $300 million for research and clinical development in the areas of cardiovascular disease, diabetes mellitus, chronic kidney disease, Orphan diseases, Alzheimer’s disease and other serious indications. In addition to garnering appropriate financing for Resverlogix’s aggressive development plan, Donald has strategically directed the company in its continued partnering discussions with global pharmaceutical companies, establishing one of the largest China biotech partnerships to date with Hepalink Pharmaceuticals.

Donald’s expertise in corporate operations has attracted an international team of experts in research, development, and corporate affairs to Resverlogix. Lead drug, apabetalone (RVX-208) has now commenced a Phase 3 clinical trial called 'BETonMACE.'  Apabetalone is a regulated drug which has the potential to be first in a new class of drugs for the reduction in Major Adverse Cardiac Events (MACE). 

As President and CEO of Resverlogix, Mr. McCaffrey spearheaded the development and spin-out of Resverlogix’s subsidiary RVX Therapeutics Inc. to Zenith Epigenetics Corp.. Zenith Epigenetics is developing bromodomain (BET) inhibitors (BRD4) for the treatment of cancer and autoimmune disorders and has an estimated enterprise value of $100 million. Mr. McCaffrey is the current President and CEO of Zenith Epigenetics and has assembled a world class Oncology team to further the development of this program. Mr. McCaffrey is also the Chairman of the Board of Directors for Zenith Epigenetics.

Donald’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year three times. Under Donald’s guidance, Resverlogix was honored with multiple awards, the most prestigious being the 2008 World Economic Forum (WEF) Technology Pioneer award in Davos Switzerland. He has also arranged support for several non-profit organizations, including the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.


Lead Director


From 1992 to 1997, Dr. Smith was Dean of the Faculty of Medicine at the University of Calgary.  From 1997 until 2010, he has been Editor-in-Chief of the Canadian Journal of Cardiology.  Dr. Smith’s research interests include circulatory mechanics, exercise physiology and echocardiography.  He has published more than 250 papers and book chapters and has been a contributor to many national and international organizations; he has been President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges and Vice President of the Inter-American Society of Cardiology.  He has served on a number of public boards including the Alberta Heritage Foundation for Medical Research, the Alberta Health Professions Advisory Board, and the Premier’s Advisory Council on Health in Alberta. He founded and served as President and Director of the Peter Lougheed Medical Research Foundation, a national initiative to support excellence in health research in Canada. He is chair of the Advisory Board of the Libin Cardiovascular Institute of Alberta and from 2006 to 2010 he was appointed by the Federal Government to chair the development of a National Strategy for Cardiovascular Health and Disease.

In addition to Resverlogix Corp., Dr. Smith currently serves on the Boards of Zenith Epigenetics Corp., Canadian Natural Resources Ltd, Intellipharmaceutics International Inc., and Aston Hill Financial.

Norma Biln



Norma Biln is the Chief Executive Officer and Co-Founder of Augurex. She has 23 years experience within large pharmaceutical and small/medium size biotech companies. Mrs. Biln began her career in clinical research and held positions within sales and marketing at Pfizer, Amgen and Abbott Laboratories where she won regional and national level awards. She later joined Stressgen Biotechnologies as Director of Corporate Market Development and Sales and Marketing. Before her role of CEO at Augurex, she worked in a senior consulting capacity with Aspreva Pharmaceuticals on business development, commercial and communications initiatives. Mrs. Biln holds a Bachelor of Science and Master of Business Administration and is Chair of the Board of Directors of BioTalent Canada.

Shawn Lu



Mr. Shawn Lu is the Chief Financial Officer of Hepalink USA Inc. Mr. Lu has extensive experience in the areas of corporate finance, capital markets and investment financing spanning over 24 years. Prior positions include: Area Manager for BMO Bank of Montreal; TD Bank Residential Mortgage Manager; TD Bank Senior Financial Advisor; Chief Financial Officer and Vice President of Corporate Finance, Shenzhen Hepalink Biopharmaceutical Co.; Vice President of Investment and Corporate Finance, Shenzhen FuTianXin Investment Co.; General Manager of Corporate Finance Department and Manager of Investment & Finance Department, China Merchant Shekou Port Co. Ltd. Mr. Lu holds the following designations: Canadian Investment Manager (CIM) and a Certified Accountant and Certified Corporate Economist in China. He has Master of Finance Management and a Master of Corporate Economics and Business Administration.

Kelly McNeill, B.Comm (Hons), M.Acc, C.A.



Mr. McNeill is currently the Chief Financial Officer at RTDS Technologies Inc, a global provider of real time digital simulators to the power systems industry, with an install base of over 1100 units in 37 countries. Prior to joining RTDS, Mr. McNeill was the Executive Vice President, Finance and Administration and Chief Financial Officer of IMRIS Inc., from 2009 through 2014.  In that role, he was responsible for leading the financial operations of the Company including M&A, capital management including a NASDAQ IPO, and its relocation of its operations from Canada to the U.S. to support its development in the advanced surgical imaging solutions field.  Prior to joining IMRIS, Kelly was part of Resverlogix's Senior Management Team from 2006 to 2009 as its Chief Financial Officer, where he was responsible for overseeing corporate finance, financial reporting, and human resources.

Prior to Resverlogix, Mr. McNeill worked at Haworth and SMED International in Calgary Alberta in the office interiors industry, serving in various management positions including the General Manager of the Canadian operations for Haworth and Vice President of Finance for SMED.  During his 9 year tenure, Mr. McNeill was part of a NASDAQ IPO and a sale of SMED to Haworth, a global office furniture manufacturer headquartered in Michigan, for $240 million.

Mr. McNeill has nearly 20 years of experience in manufacturing and technology organizations, both large and small, with experience in M&A, raising capital in public equity markets, and managing complex operations around the globe. 

Mr. McNeill is a chartered accountant and earned a B.Comm (Hons) and M.Acc from the University of Manitoba and is currently a member of the Board of Directors of Zenith Epigenetics.

Kenneth J. Zuerblis



Mr. Zuerblis was formerly Executive Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc., a position he held until May 2012. Prior to joining Savient, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President at ImClone Systems from 2008 through 2009. In that role, he was responsible for the strategic planning and leadership of finance and related operations and helped lead all aspects of the sale of the company to Eli Lilly and Company. From 1994 through 2005, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc., and held the position of Corporate Controller from 1991 through 1994. Enzon developed the first three FDA approved products using PEGylation technology. Most notably during Mr. Zuerblis’ 14 year tenure, Enzon transformed from an early stage biotechnology company into a fully integrated biopharmaceutical company with five marketed products.

He began his career at KPMG, LLP in 1982 where he held management positions of increasing responsibility over a 10 year period. Mr. Zuerblis brings nearly 30 years of proven leadership expertise in building fully integrated biopharmaceutical organizations and has an established track record of managing complex commercial and research organizations, raising capital, overseeing multifaceted merger and acquisition transactions, and directing all investor and shareholder relations.

Mr. Zuerblis earned his Bachelor of Science in Accounting from Seton Hall University and is a certified public accountant in the State of New Jersey.

Mr. Zuerblis is currently a member of the Board of Directors of Resverlogix Corp., Zenith Epigenetics Corp. and Stemline Therapeutics.